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Widespread diversion of antiretroviral (ARV) medications to illicit markets has recently been documented among
indigent patients in South Florida. The recent approval of ARVs for pre-exposure prophylaxis (PrEP) has the potential to
broaden these illicit markets, as high-risk individuals seek ARVs without a prescription or medical supervision.
Nonadherence among diverters and unsupervised use of ARVs for treatment or PrEP increase risks of treatment failure,
drug resistance, and disease transmission. We report the scope of ARV diversion among substance-using men who have
sex with men in South Florida. Structured interviews (N = 515) queried demographics, HIV status, mental distress,
substance dependence, and sexual risks. HIV-positive participants answered questions about medical care, treatment, and
ARV adherence and diversion. Median age was 39. Of 46.4% who were HIV-positive, 79.1% were prescribed ARVs. Of
these, 27% reported selling/trading ARVs. Reasons for diversion were sharing/trading with friends, sale/trade for money/
drugs, and sale/trade of unused medications. ARV diverters, compared to nondiverters, were more likely to be substance
dependent (74.5% vs. 58.7%, p = 0.046) and have traded sex for money/drugs (60.8% vs. 32.6%, p < 0.001), and less
likely to be adherent to ARVs (54.9% vs. 73.9%, p = 0.012). ARV diversion should be a particular concern in
communities of high-risk men who have sex with men as uninfected men in such communities are likely to benefit most
from PrEP but unlikely to have access to PrEP and necessary ancillary services through the health-care system. The
implications of diversion for increased risks of treatment failure, disease transmission, and PrEP failure should be
carefully considered in developing policy and behavioral supports to scaling up treatment as prevention and PrEP.
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Introduction
Widespread diversion – the unlawful channeling of
regulated pharmaceuticals to illicit markets (Inciardi,
Surratt, Kurtz, & Burke, 2006) – of antiretrovirals (ARVs)
has recently been documented in South Florida among
vulnerable, indigent patients who are targeted by pill
brokers to trade their ARVs for money and/or drugs
(Surratt, Kurtz, Cicero, O’Grady, & Levi-Minzi, 2013).
Large-scale diversion of ARVs has also been detected in
several other locations (Associated Press, 1995; Dorschner,
2005; Flaherty & Gaul, 2003; Glasgow, 1999; Surratt &
Kurtz, 2013), with law enforcement activities disrupting
ARV diversion networks in no fewer than seven states.
Beyond these organized profit-making enterprises, a few
reports indicate that ARV diversion also occurs for the
purposes of getting high on medications with known
psychoactive properties (Grelotti, Closson, & Mimiaga,
2013; Inciardi, Surratt, Kurtz, & Cicero, 2007), or for
nonprescribed pre- or post-exposure prophylaxis (PrEP
/PEP) (Liu et al., 2008; Mansergh et al., 2010; Mimiaga,
Case, Johnson, Safren, & Mayer, 2009). In this regard,
emtricitabine/tenofovir, the only US Food and Drug
Administration (FDA, 2012)-approved medication for
PrEP, is among the most frequently diverted ARV
according to recent reports by both law enforcement
and patients (O’Grady, Surratt, & Kurtz, 2013; Surratt &
Kurtz, 2013). The selling and trading of ARVs are
associated with nonadherence among diverters (Surratt
et al., 2013), increasing the risk of treatment failure and
disease transmission (Bangsberg et al., 2001), as well as
drug resistance and PrEP failure among nonmedically
supervised end users (Hurt, Eron, & Cohen, 2011).
The recent approval by the FDA of ARVs for PrEP
(FDA, 2012), together with the earlier issuance by the US
Centers for Disease Control and Prevention (CDC) of
interim guidance for the clinical administration of PrEP
(CDC, 2012; Smith et al., 2011), has the potential to
broaden illicit markets for ARVs, as at-risk individuals –
many lacking financial resources or health coverage
(Curran & Crosby, 2013) – seek them without medical
supervision or behavioral support. Although ARV diver-
sion is also potentially a concern for unsupervised use by
uninsured HIV-positive patients in search of ARVs for self-
treatment, the widespread availability of low-cost treatment
for HIV-positive patients in the USA, together with the
multiple and often complex treatment regimens for HIV
infection, would appear to limit the use of diverted medi-
cations for this purpose. On the other hand, the approved
*Corresponding author. Email: steven.kurtz@nova.edu
© 2013 Taylor & Francis
AIDS Care, 2014
Vol. 26, No. 4, 411–415, http://dx.doi.org/10.1080/09540121.2013.837139
PrEP regimen consists of a single well-recognized product,
and the nonprescribed use of emtricitabine/tenofovir
for prevention (e.g., “Methamphetamine, Truvada and
Viagra [MTV] party packs,” “disco dosing,” “taking a T”)
has been documented among high-risk men who have sex
with men (MSM) since at least 2009 (Philpott, 2013;
D. Fawcett, personal communication, June 1, 2013).
Here, we describe the diversion of ARVs among a
highly vulnerable sample of HIV-positive substance-
using MSM as reported in interviews conducted during
the period November 2008 through October 2011 as a
part of their participation in an intervention trial.
Methods
The MSM study is a randomized clinical trial of a
behavioral intervention targeted to high-risk substance-
using MSM in South Florida. Eligible men were aged
18–55 and reported recent (in the past 90 days) unprotec-
ted anal intercourse (UAI) with a nonmonogamous
partner(s), and met one or more of three substance use
inclusion criteria: binge drinking (five or more drinks) or
drug use, excluding marijuana, at least three times, or
marijuana use at least 20 days, in the past month.
Data reported here are drawn from standardized
interviewer-administered baseline assessments (N = 515)
conducted between November 2008 and October 2011
that included measures of demographics, self-reported
HIV status, sexual risk behaviors, and Diagnostic Statist-
ical Manual IVR (DSM-IVR) clinical measures of mental
distress and substance dependence (Dennis, Titus, White,
Unsicker, & Hodgkins, 2002). HIV-positive participants
also answered questions about medical care and treat-
ment; self-reported past month ARVadherence; and ARV
diversion history. Reasons for diverting ARVs were
assessed with open-ended responses that were coded
into well-defined categories. Research protocols were
approved by the University of Delaware’s (predecessor
institution) and Nova Southeastern University’s Institu-
tional Review Boards.
For the analyses presented here, descriptive statistics
were used to characterize the study sample. Chi-square
and analysis of variance tests examined the differences
between HIV-positive participants with ARV prescrip-
tions who had sold or traded their ARV medications
compared to those who had not done so.
Results
Characteristics of the total sample and the sample of
HIV-positive men with ARV prescriptions are shown
in Table 1. Mean age of the full sample was 38.9
Table 1. Baseline characteristics of substance-using MSM.
Total sample (N = 515) HIV + w/ARV prescription (N = 189)
N % N %
Demographics
Age (mean; SD) 38.9 (9.6) 43.4 (7.2)
Education (mean; SD) 13.8 (2.4) 13.7 (2.3)
Race/Ethnicity
Hispanic 133 25.8 40 21.1
African-American/Caribbean 108 21.0 47 24.9
Caucasian 250 48.5 93 49.2
Other 24 4.7 9 4.8
Homeless in the past year 133 25.8 52 27.5
Sex-risk behavior (past 90 days)
Anal sex partners (mean; SD) 13.3 (18.6) 15.6 (19.8)
UAI times (mean; SD) 22.6 (35.4) 26.1 (34.9)
Traded sex (past 12 months) 176 34.2 76 40.2
Health-risk measures
Severe mental distress 298 57.9 122 64.6
DSM-IVR substance dependence 156 62.1 119 63.0
Victimized before age 18 282 54.8 101 53.4
Health-care coverage
HIV-negative 276 53.6 –
Health-care coverage 117 42.4 –
HIV-positive 239 46.4 –
Health-care coverage 206 86.2 –
Receiving HIV medical care 219 91.6 –
Prescribed ARV medications 189 79.1 –
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(SD = 9.6); mean years of education, 13.8 (SD = 2.4).
Race/ethnicity: 48.5% White, 25.8% Hispanic, 21.0%
African-American/Caribbean, and 4.7% other. More than
one-quarter (25.8%) reported the past year homelessness.
Participants reported high levels of sexual risk behaviors,
including an average of 13.3 (SD = 18.6) anal sex
partners and 22.6 (SD = 35.4) UAI events in the past
90 days; 34.2% had traded sex for money or drugs in
the past year. Majorities met clinical criteria for severe
mental distress (57.9%) and substance dependence
(62.1%), and had been victimized as minors (54.8%).
Almost half (42.4%) were HIV-positive. HIV-positive
men with ARV prescriptions reported demographic and
health-risk profiles that were similar to the full sample.
Fewer than half (42.4%) of HIV-negative men had
health-care coverage, defined as any type of insurance or
program to pay health expenses. Of the HIV-positive
men, the large majority reported health-care coverage
(86.2%) and were receiving medical care at that time
(91.6%); 79.1% were prescribed ARV medication. Of the
latter group (n = 189), 27.0% (n = 51) reported having
ever sold and/or traded their ARVs (diverters); 19.0%
had done so in the past year. Reasons for diversion were
(more than one reason was permissible) share/trade
with friends (n = 32; 62.7% of diverters); sale/trade for
money and/or drugs (n = 19; 37.3%); donated leftover
medications to a clinic or organization (n = 10; 19.6%);
and, sale/trade of medications that were no longer used
(n = 5; 9.8%). Two participants (3.9% of diverters) who
donated their leftover medications to a clinic or organ-
ization did not engage in any other types of diversion
activities. Such donations would not likely find their way
into illicit markets, although the nature of the donee
organizations is unknown.
Characteristics of participants with ARV prescrip-
tions by diversion status are shown in Table 2. ARV
diverters, compared to nondiverters, were more likely to
be substance dependent (74.5% vs. 58.7%, p = 0.046)
and to have recently traded sex for money/drugs (60.8%
vs. 32.6%, p < 0.001), and less likely to be 90% adherent
to their ARVs (54.9% vs. 73.9%, p = 0.012).
Discussion
The diversion of ARVs is a largely unrecognized
problem in the USA, but has been documented in no
fewer than seven states (Surratt & Kurtz, 2013). ARV
diversion was also reported by more than one-quarter of
HIV-positive participants with prescriptions in our inter-
vention trial for high-risk, substance-using MSM. HIV-
negative men in these high-risk networks are among the
highest priority for PrEP rollout (Smith et al., 2011), the
most likely to benefit from PrEP (Curran & Crosby,
2013), and, if successfully targeted, the most likely to
produce population-level improvements in the US HIV
epidemic in a cost-effective way (Juusola, Brandeau,
Owens, & Bendavid, 2012). Moreover, MSM are known
to be early adopters of new behavioral and biological
HIV prevention technologies (Kippax, 2012). Indeed, the
nonprescribed use of emtricitabine/tenofovir for preven-
tion has been documented among high-risk MSM since at
Table 2. Correlates of ARV diversion among MSM with prescriptions (N = 189).
Diverters (N = 51) Nondiverters (N = 138)
N % N % p
Demographics
Age (mean; SD) 42.3 (6.9) 43.8 (7.2) 0.211
Education (mean; SD) 13.6 (2.1) 13.7 (2.3) 0.932
Race/Ethnicity
Hispanic (ref.) 9 17.6 31 22.5
African-American/Caribbean 18 35.3 29 21.0 0.067
Caucasian 22 43.1 71 51.4 0.644
Other 2 4.0 7 5.1 0.881
Homeless in the past year 17 33.3 35 25.4 0.276
Sex-risk behavior (past 90 days)
Anal sex partners (mean; SD) 14.7 (21.3) 16.0 (19.3) 0.695
UAI times (mean; SD) 21.4 (23.8) 27.9 (38.1) 0.255
Traded sex (past 12 months) 31 60.8 45 32.6 <0.001
Health-risk measures
Severe mental distress 34 66.7 88 63.8 0.712
DSM-IVR substance dependence 38 74.5 81 58.7 0.046
Victimized before age 18 30 58.8 71 51.4 0.367
90% adherent to ARVs 28 54.90 102 73.9 0.012
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least 2009 (Philpott, 2013; D. Fawcett, personal com-
munication, June 1, 2013).
Although there is wide agreement among govern-
mental agencies and scientists that individuals taking
PrEP require frequent testing, regular health monitoring,
and ongoing behavioral support (Koenig, Lyles, &
Smith, 2013; Smith et al., 2011; Weber, Tatoud, &
Fidler, 2010), MSM at highest risk for HIV infection are
likely to have difficulty accessing these services. Data
from our sample confirm others’ concerns (Curran &
Crosby, 2013; Koenig et al., 2013) that MSM who would
most benefit from PrEP suffer high rates of substance
use and have limited access to health care. Only 42.4%
of HIV-negative men in our study had any type of
health-care coverage. These vulnerabilities render them
less likely to have access to prescribed PrEP, medical
supervision, and ancillary services. Nevertheless, this
population of sexually active men is likely to have a high
level of interest in PrEP (Krakower et al., 2012; Liu
et al., 2008; Mimiaga et al., 2009), and, because their
health and social vulnerabilities, to be at risk for
attempting access to PrEP through nonmedical channels.
Several limitations of the study design must be
considered in evaluating the findings. First, the data
rely on self-report, and some respondents may have
refrained from reporting socially undesirable behaviors.
In the present case, however, that would likely mean
underreporting of diversion. Also, the prevalence of
diversion among HIV-positive MSM found here is not
necessarily generalizable to the overall population of
HIV-positive MSM because of the eligibility require-
ments, requiring recent substance abuse and UAI.
Importantly, we did not collect data from HIV-negative
men on their use of diverted ARVs; as such, our data
confirm only the supply side of illicit markets. We do not
know the characteristics of the end users of the diverted
medications, nor their reasons for use.
Our findings indicate that street markets for ARVs
approved for PrEP are already active. We have focused
our analysis on the risks posed by ARV diversion to the
successful rollout of PrEP rather than self-treatment for
several reasons: (1) nonprescribed use of emtricitiabine/
tenofovir for prevention has been documented among
high-risk MSM since well before the issuance of CDC
guidance or FDA approval; (2) the great difference in
access to health care between HIV-positive and HIV-
negative MSM; over 90% of the HIV-positive men in our
high-risk sample were in care; (3) the simplicity of the
PrEP regimen compared to regimens for the treatment of
HIV infection and PEP; and (4) the lack of evidence for
diverted ARVs being used for self-treatment. At the
same time, the scale-up of treatment as prevention will
potentially increase the supply of divertable ARVs.
As high-risk MSM become more aware of the use of
ARVs for PrEP, illicit markets may expand based on this
new source of demand. In this informal illicit market
sector, knowledge gaps, inconsistent ARV supplies and
adherence, and lack of frequent testing and ongoing
behavioral support may lead to sporadic use, unmoni-
tored restarts, use when unknowingly infected, and,
potentially, the use of counterfeit, ineffective, or com-
promised ARVs. Confusion over which drugs and
dosages are approved for PrEP is also a concern (Weber
et al., 2010). For PrEP to succeed in reducing HIV
infections among at-risk populations, expanded health-
care coverage, robust outreach programs, and access to
services not directly related to HIV, including mental
health and substance-abuse treatment, will be critical.
Our findings point to the need for more research on
the scope and magnitude of ARV diversion, with a
particular focus on how the rollout of treatment as
prevention and PrEP impacts illicit markets for these
medications. Moreover, it is important that clinicians be
aware of ARV street markets, and the potential for such
markets to result in patients’ low adherence and
increased risk for health problems, ARV resistance, and
onward disease transmission. At the same time, care
must be taken not to restrict patients’ supplies such that
office visits are too frequent to be manageable, or that
patients are at risk for nonadherence because of running
out of medication. Most importantly, ARV diversion –
and related risks of treatment failure, resistance, disease
transmission, and PrEP failure – should be considered in
developing policy and behavioral supports to scaling up
treatment as prevention and PrEP.
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